Drug Development Partners

Drug Development Partners (DDP) is a new alliance (established in 2006) between IATEC and Kinesis that covers all aspects of drug development – from early selection of research opportunities to full execution of global clinical trials. DDP provides a comprehensive package of preclinical and clinical consultancy and contract services covering every aspect of the drug development life cycle. These services range from early Chemistry, Manufacturing & Control (CM&C) studies and formulation development to the final stage of multinational registration studies.

Together, IATEC and Kinesis have conducted about 80 full clinical trials and studies (from Phase I-IV, including observational and pre-clinical studies). In addition, they have executed more than 200 other contracts within the realm of clinical trial services. With more than 100 global trial locations with a full spread over the globe, DDP has access to diverse and large patient populations in the world and is able to perform both small local trials and complex multi-sponsor, multi-national programs. Many of these sites are located in cost-efficient settings, providing significant potential for savings on study costs, while maintaining the highest standards of quality.

Within DDP IATEC and Kinesis provide top-quality services, offer the highest possible objectivity in every approach, and deliver their services on time and within budget. DDP works for all R&D departments of pharmaceutical and biotech companies.

IATEC is an independent, full-service Contract Research Organization (CRO); its headquarters are located in Amsterdam, the Netherlands. IATEC offers a comprehensive package of research services for the pharmaceutical industry and has extensive experience in Phase I, II, III and IV trials in areas as diverse as dermatology, oncology, endocrinology, urology, cardiovascular illnesses, CNS, virology and the respiratory-pulmonary system.

Kinesis is located in Breda, the Netherlands, and is a specialist in the development of preclinical and clinical R&D strategies, ranging from exploratory development to the pivotal non-clinical and phase I and IIA clinical studies needed for regulatory filing. Kinesis designs and executes exploratory pre-clinical toxicology and pharmacokinetic selection programs for sets of late lead candidates. In addition, Kinesis designs and executes early preclinical and clinical development programs and drug-drug interaction programs.

(c) 2008, Amsterdam

	IATEC Clinical Trial Services Antiviral Research 1105 BM Amsterdam The Netherlands Phone: +31 (0)20 314 9300 Fax: +31 (0)20 314 9399 secretariat@iatec.com More information about IATEC at www.iatec.com